The vast majority of PPARγ/RXRα active tumors were presented in Cluster I, a subset of luminal bladder cancer, suggesting PPARγ/RXRα activation may contribute to lack of response to immunotherapy (Supplementary Fig. 25). Here, RXRA is linked to urinary bladder cancer.